Today we reported our financial results for the second quarter of 2026 and highlighted recent progress across our business. https://lnkd.in/giqzmspd
uniQure
Biotechnologisch onderzoek
Amsterdam, 1105BP 33.408 volgers
Transforming the lives of patients through gene therapy
Over ons
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
- Website
-
http://www.uniQure.com/
Externe link voor uniQure
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 51 - 200 medewerkers
- Hoofdkantoor
- Amsterdam, 1105BP
- Type
- Naamloze vennootschap
- Opgericht
- 1998
- Specialismen
- aav, Huntington's disease, gene therapy, ALS, epilepsy en Fabry disease
Locaties
-
Primair
Routebeschrijving
Paasheuvelweg 25a
Amsterdam, 1105BP 1105BP, NL
-
Routebeschrijving
1 Hartwell Pl
Lexington, Massachusetts 02421, US
Medewerkers van uniQure
Updates
-
Thank you to Help4HD for hosting a wonderful HIPE Event in L.A. this past weekend. As a proud sponsor, uniQure was honored to present and connect with the Huntington's disease community. We appreciate Help4HD's commitment to informing and empowering HD families. #HuntingtonsDisease
-
-
The #HDSAConvention concluded a fantastic event with its Awards Dinner & Gala, highlighted by the moving candlelighting ceremony. This powerful tradition honors those the community has lost and those we are all fighting for. The light symbolizes the courage of caregivers, the strength of advocates, the brilliance of researchers, and the resilience of families. We were deeply honored to take part. Thank you Huntington's Disease Society of America for an inspiring and energizing weekend.
-
-
The Opening Ceremony of today's #HDSAConvention included an update from uniQure following our recent AMT-130 regulatory news. uniQure Patient Advocacy's Payal Venugopal outlined next steps and expressed our sincere gratitude to the community: "We want to say a heartfelt thank you to the #HuntingtonsDisease community. Patients, families, and advocacy partners are truly at the center of this work. Your willingness to share your experiences has helped ensure the patient voice is heard... We also recognize the critical role of clinical trial participation and advocacy. Efforts like Enroll-HD, participation in research, and ongoing advocacy have been essential in advancing understanding of HD. Every contribution has helped drive meaningful progress and key milestones... A big thank you to HDSA for your continued advocacy efforts including the recent meetings with lawmakers and shaping the next advocacy patient leaders, many of whom are in this room. To the HD Coalition leaders, advances in this field are possible because of this partnership. Your collaboration is helping move science forward and bringing us closer to new treatment options."
-
-
We're thrilled to be in Phoenix this weekend for this year's #HDSAConvention! If you're in attendance, please drop by our booth in the Exhibit Hall to learn more about uniQure and our AMT-130 #genetherapy program for #HuntingtonsDisease. #LetsTalkAboutHD
-
-
Today we provided a regulatory update on a path forward for AMT-130, our investigational gene therapy for Huntington’s disease, following a meeting with the FDA. Read the full update here: https://lnkd.in/e_FtDPjs
-
Thank you Gina Kolata of The New York Times for shining light on the realities that Huntington’s disease patients and their families face every day. The profile of Nancy Wexler, who dedicated her life to understanding this disease while living with it herself, is a powerful reminder of what is at stake for the thousands of Americans still waiting for a treatment. We’re working hard to change one crucial piece of this reporting: that there is currently no treatment for #HuntingtonsDisease. Read the full article here: https://lnkd.in/e-T-3DsX
-
The uniQure team was proud to walk alongside the Huntington's Disease Society of America (HDSA) at Boston's Castle Island today! Our spirited group participated in the Team Hope Walk, raising vital funds for HD research, family services, and advocacy. Together, we’re walking toward a treatment for #HuntingtonsDisease.
-
-
Our Lexington team rolled up our sleeves recently for uniQure's first community service event with Life Science Cares Boston, assembling nearly 300 hygiene kits for youth served by Bridge Over Troubled Waters -- each one packed with essentials and a hand-written note of encouragement. It was a fast-paced and fun afternoon, providing an opportunity to connect with colleagues while helping the community.
-
-
May is Huntington's Disease Awareness Month, and this week we had a powerful opportunity to hear directly from the #huntingtonsdisease community we work for every day, as we welcomed rare disease advocate and author Erin Paterson to our Lexington office for a fireside chat. Erin is gene positive and a caregiver for her father, who is living with HD. She spoke candidly about the challenges of caregiving and depression as well as the power of community and positivity. We are grateful to Erin for sharing her story with us in recognition of #HDAwarenessMonth.
-